Published in Law and Health Weekly, March 12th, 2005
One source of hope for pharmaceutical companies lies in the release of extension products. If a company can introduce an extension, such as an extended release version for the drug, 6 months or a year before an existing drug's patent expires, it has a chance to shift patients to the new, patent- protected drug.
If this strategy is successful, the company can retain market share even after generic copies of the original drug reach market. Without a line extension, companies risk losing 80% or greater market share to less expensive generics.
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Law and Health Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.